Phase 3 study of OBI-822 in patients with Metastatic Breast Cancer
Phase of Trial: Phase III
Latest Information Update: 01 Mar 2017
At a glance
- Drugs Adagloxad simolenin (Primary)
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors OBI Pharma
- 01 Mar 2017 According to Amaran Biotechnology media release, OBI Pharma received formal approval from the China Food and Drug Administration to conduct Phase 3 study.
- 25 Jan 2017 According to an OBI Pharma media release, this trial could be used in a future Biologics License Application (BLA) submission, subject to future amendment.
- 24 Feb 2016 New trial record